JP6431920B2 - 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 - Google Patents
免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 Download PDFInfo
- Publication number
- JP6431920B2 JP6431920B2 JP2016543472A JP2016543472A JP6431920B2 JP 6431920 B2 JP6431920 B2 JP 6431920B2 JP 2016543472 A JP2016543472 A JP 2016543472A JP 2016543472 A JP2016543472 A JP 2016543472A JP 6431920 B2 JP6431920 B2 JP 6431920B2
- Authority
- JP
- Japan
- Prior art keywords
- klh
- globo
- cancer
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 166
- 206010028980 Neoplasm Diseases 0.000 title claims description 93
- 201000011510 cancer Diseases 0.000 title claims description 57
- 238000011282 treatment Methods 0.000 title claims description 30
- 229960005486 vaccine Drugs 0.000 title description 23
- 230000028993 immune response Effects 0.000 title description 12
- 125000000837 carbohydrate group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 102
- 210000004027 cell Anatomy 0.000 claims description 58
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- 239000002671 adjuvant Substances 0.000 claims description 41
- 230000000890 antigenic effect Effects 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 239000013638 trimer Substances 0.000 claims description 26
- 239000000539 dimer Substances 0.000 claims description 25
- 239000000178 monomer Substances 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 22
- 229930182490 saponin Natural products 0.000 claims description 22
- 150000007949 saponins Chemical class 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 21
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 238000002626 targeted therapy Methods 0.000 claims description 15
- 238000009169 immunotherapy Methods 0.000 claims description 14
- 230000004083 survival effect Effects 0.000 claims description 13
- -1 cancer vaccines Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 201000009030 Carcinoma Diseases 0.000 claims description 10
- 102000019034 Chemokines Human genes 0.000 claims description 10
- 108010012236 Chemokines Proteins 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 238000009566 cancer vaccine Methods 0.000 claims description 7
- 229940022399 cancer vaccine Drugs 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 230000001028 anti-proliverative effect Effects 0.000 claims description 6
- 230000036457 multidrug resistance Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 6
- 229930186217 Glycolipid Natural products 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 108010028921 Lipopeptides Proteins 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 108091029523 CpG island Proteins 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims description 3
- 108060006698 EGF receptor Proteins 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 108010040721 Flagellin Proteins 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 102000003810 Interleukin-18 Human genes 0.000 claims description 3
- 108090000171 Interleukin-18 Proteins 0.000 claims description 3
- 102100030703 Interleukin-22 Human genes 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000012828 PI3K inhibitor Substances 0.000 claims description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 3
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 3
- 108010078233 Thymalfasin Proteins 0.000 claims description 3
- 102000002689 Toll-like receptor Human genes 0.000 claims description 3
- 108020000411 Toll-like receptor Proteins 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
- 230000003474 anti-emetic effect Effects 0.000 claims description 3
- 239000002111 antiemetic agent Substances 0.000 claims description 3
- 229940125683 antiemetic agent Drugs 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 230000011712 cell development Effects 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 230000000091 immunopotentiator Effects 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 108010074108 interleukin-21 Proteins 0.000 claims description 3
- 229960001614 levamisole Drugs 0.000 claims description 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004961 mechlorethamine Drugs 0.000 claims description 3
- 208000004235 neutropenia Diseases 0.000 claims description 3
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 3
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 3
- 102000027483 retinoid hormone receptors Human genes 0.000 claims description 3
- 108091008679 retinoid hormone receptors Proteins 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 3
- 229960004231 thymalfasin Drugs 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 229940126638 Akt inhibitor Drugs 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 2
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 108020000999 Viral RNA Proteins 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000001672 cytoproliferative effect Effects 0.000 claims description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims description 2
- 229940075993 receptor modulator Drugs 0.000 claims description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 2
- 239000003558 transferase inhibitor Substances 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 268
- 230000001225 therapeutic effect Effects 0.000 description 162
- 108090000765 processed proteins & peptides Proteins 0.000 description 92
- 101100123569 Megathura crenulata KLH1 gene Proteins 0.000 description 65
- 101100123570 Megathura crenulata KLH2 gene Proteins 0.000 description 65
- 235000018977 lysine Nutrition 0.000 description 58
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 51
- 238000004458 analytical method Methods 0.000 description 40
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 39
- 239000004472 Lysine Substances 0.000 description 39
- 230000021615 conjugation Effects 0.000 description 39
- 238000000034 method Methods 0.000 description 38
- 230000003211 malignant effect Effects 0.000 description 33
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 31
- 102000004190 Enzymes Human genes 0.000 description 28
- 108090000790 Enzymes Proteins 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 150000002500 ions Chemical class 0.000 description 24
- 230000004048 modification Effects 0.000 description 23
- 238000012986 modification Methods 0.000 description 23
- 235000017709 saponins Nutrition 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 108090000317 Chymotrypsin Proteins 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 108090001109 Thermolysin Proteins 0.000 description 18
- 108090000631 Trypsin Proteins 0.000 description 18
- 102000004142 Trypsin Human genes 0.000 description 18
- 229960002376 chymotrypsin Drugs 0.000 description 18
- 239000012588 trypsin Substances 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 150000004676 glycans Chemical class 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 150000001720 carbohydrates Chemical class 0.000 description 16
- 235000014633 carbohydrates Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 230000003053 immunization Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 125000005647 linker group Chemical group 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- MGSDFCKWGHNUSM-QVPNGJTFSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O MGSDFCKWGHNUSM-QVPNGJTFSA-N 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229930182470 glycoside Natural products 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- ASNHGEVAWNWCRQ-WDCZJNDASA-N beta-D-Apiose Natural products OC[C@@]1(O)[C@H](O)[C@H](O)OC1 ASNHGEVAWNWCRQ-WDCZJNDASA-N 0.000 description 6
- ASNHGEVAWNWCRQ-VPENINKCSA-N beta-D-apiose Chemical compound OC[C@@]1(O)CO[C@@H](O)[C@@H]1O ASNHGEVAWNWCRQ-VPENINKCSA-N 0.000 description 6
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 6
- 108060003552 hemocyanin Proteins 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000237536 Mytilus edulis Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000020638 mussel Nutrition 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- IZMMAJINAROYPF-UHFFFAOYSA-N 2H-thiophen-5-imine Chemical compound N=C1SCC=C1 IZMMAJINAROYPF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101100400624 Caenorhabditis elegans mbr-1 gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 210000004565 granule cell Anatomy 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000894590 Homo sapiens Uncharacterized protein C20orf85 Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 241000542855 Megathura crenulata Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241001454523 Quillaja saponaria Species 0.000 description 2
- 235000009001 Quillaja saponaria Nutrition 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100021442 Uncharacterized protein C20orf85 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000012820 cell cycle checkpoint Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 108700033056 globo H-keyhole limpet hemocyanin QS-21 vaccine Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000005949 ozonolysis reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000004725 rapid separation liquid chromatography Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000006177 thiolation reaction Methods 0.000 description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SFFUEHODRAXXIA-UHFFFAOYSA-N 2,2,2-trifluoroacetonitrile Chemical compound FC(F)(F)C#N SFFUEHODRAXXIA-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 108050005711 C Chemokine Proteins 0.000 description 1
- 102000017483 C chemokine Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 1
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- UPCIBFUJJLCOQG-UHFFFAOYSA-L ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethyl-methylamino]ethyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC UPCIBFUJJLCOQG-UHFFFAOYSA-L 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical group NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 208000028676 malignant spindle cell neoplasm Diseases 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
かかるリジン抱合部位が各KLH成分サブユニット上に62、66、67、68、70、72、76、86、87、88、90、92、93、100個ある。
一定の具体的な態様において、本発明の範囲にはまた、単離された治療用の抗体であって本明細書に開示される治療用抱合体に親和性があり特異的に結合するものが含まれ、さらに増殖性疾患の治療及び/又は診断におけるそれらの使用が含まれる。
一態様において、患者に投与された時、本発明の治療用抱合体を含有する治療用組成物は、同じ試験において、抗Globo H抗体の力価を、投与前(すなわち治療前の基準となる力価)の同じ抗Globo H抗体の力価に比べて、少なくとも又は約1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、50、100、250、500、1000、1500、2000、2500、3000、4000、若しくは5000倍に高めることができる。一定の態様において、抗Globo H抗体はIgM抗体である。他の一態様において、抗Globo H抗体はIgG抗体である。
治療用組成物には、他の抗がん/抗増殖剤が含まれていてもよく、またアジュバント及び、サイトカインやケモカインのような他の免疫調節因子が含まれていてもよい。これらの剤はいずれも、別体の容器又は一つの容器に入れられて、キットとして一緒に供給されるものでもよい。上記の剤は投与の時に組み合わせてもよく、また投与の少なくとも又は約1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23若しくは24分前、時間前又は日前に組み合わせてもよい。
ここで
R1はβ−D−アピオース又はβ−D−キシロースであり、また
R2及びR3は各々H、アルキル、
(i) R1がβ−D−アピオースであり、R2が上述の1989化合物の脂肪族アシル成分であり、またR3がHである(1989化合物V1A);
(ii) (ii)R1がβ−D−アピオースであり、R2がHであり、またR3が上述の1989化合物の脂肪族アシル成分である(1989化合物V1B);
(iii) (iii)R1がβ−D−キシロースであり、R2が上述の1989化合物の脂肪族アシル成分であり、またR3がHである(1989化合物V2A);または
(iv) (iv)R1がβ−D−キシロースであり、R2がHであり、またR3が上述の1989化合物の脂肪族アシル成分である(1989化合物V2B);1989化合物V1A、1989化合物V1B、1989化合物V2A及び1989化合物V2Bをまとめたものを「1989化合物混合物」と呼ぶものとする。
(i) R1がβ−D−アピオースであり、R2が上述の1857化合物の脂肪族アシル成分であり、またR3がHである(1857化合物V1A);
(ii) R1がβ−D−アピオースであり、R2がHであり、またR3が上述の1857化合物の脂肪族アシル成分である(1857化合物V1B);
(iii) R1がβ−D−キシロースであり、R2が上述の1857化合物の脂肪族アシル成分であり、またR3がHである(1857化合物V2A);または
(iv) R1がβ−D−キシロースであり、R2がHであり、またR3が上述の1857化合物の脂肪族アシル成分である(1857化合物V2B);1857化合物V1A、1857化合物V1B、1857化合物V2A及び1857化合物V2Bをまとめたものを「1857化合物混合物」と呼ぶものとする。
(i)1857化合物V1A;(ii)1857化合物V1B;
(ii)1857化合物V2A;
(iii)1857化合物V2B;
(iv)1989化合物V1A;
(v)1989化合物V1B;
(vi)1989化合物V2A;又は
(vii)1989化合物V2B。
(i)1857化合物混合物で構成されるOBI-821を約1モル%から約15モル%
(ii)1989化合物混合物で構成されるOBI-821を約85モル%から約99モル%
ここで、
R1はβ−D−アピオース又はβ−D−キシロースであり、また
R2及びR3は各々H、アルキル、
及び薬剤として許容可能なキャリアである。
治療用組成物(また本明細書において医薬組成物とされるもの)には、総じて、薬剤として許容可能なキャリアが含まれていてもよい。本明細書において用いられるように、「薬剤として許容可能なキャリア("pharmaceutically acceptable carrier")」の言葉には、溶媒、分散媒、コーティング、抗菌剤及び抗真菌剤、等張性のための及び吸収遅延のための剤等の薬剤としての投与に適合するものが含まれる。また補助活性物質を組成物に取り入れてもよい。医薬組成物は意図した投与経路に適合するように処方される。投与経路の例には、腸管外投与、例えば静脈内、皮内、皮下、筋肉内、動脈内、経口(吸入等)、経皮(局所)、経粘膜、及び直腸の各投与経路がある。腸管外、皮内、又は皮下に適用するための溶液又は懸濁液には以下の成分が含まれていてもよい:水のような注射のための滅菌希釈剤、生理食塩水、リン酸塩緩衝食塩水、トリス緩衝食塩水、不揮発油、ポリエチレングリコール、グリセリン、プロピレングリコール又は他の合成溶媒;ベンジルアルコール又はメチルパラベンなどの抗菌剤;アスコルビン酸又は亜硫酸水素ナトリウムなどの抗酸化剤;エチレンジアミン四酢酸などのキレート剤;酢酸塩、クエン酸塩、又はリン酸塩等の緩衝液及び塩化ナトリウム又はデキストロース等の浸透圧の調整のための薬剤。pHは塩酸又は水酸化ナトリウムなどの酸又は塩基により調整してもよい。腸管外の製剤はアンプル、使い捨ての注射筒、又は複数回の分量のバイアルであってガラス又はプラスチック製のものに封入してもよい。
上記治療用組成物の毒性及び治療効果の評価は細胞培養又は実験動物における標準的な薬学的手法、例えばLD50(集団中の50%が致死となる用量)及びED50(集団中の50%に治療効果のある用量)の決定により行うことができる。毒性のある用量と及び治療効果のある用量の比が治療指数であり、LD50/ED50の比で表してもよい。治療用組成物は治療指数の大きいことが好ましい。副作用としての毒性を有する化合物を使用してもよいが、患部を上記化合物の標的とする送達系を設計することに注意を払うことで、非感染細胞に対する潜在的な被害を最小限とし、副作用を減らす必要がある。
他の観点において、当業者であれば、一又は二以上の、キット(パートの一式、kits of parts)を認識することができる。かかるキットによって本明細書で開示される一以上の方法を実施できる。キットは、一又は二以上の治療用抱合体、抗がん剤/抗増殖剤、アジュバント、サイトカイン及び/又はケモカインから構成される。一以上の上記方法に沿って本明細書で開示される有効量の治療用組成物を単独で又は組み合わせて構成される治療用組成物。上述の剤は単一の容器に入れてもよく、またキット中の異なる容器に入れてもよい。
本発明の治療用組成物におけるGlobo Hの六糖成分はアリルグリコシドとして化学的に合成してからKLHとの抱合体を調製した。
テーブル4:KLHに対するGlobo Hの分子比の算出
テーブル5:免疫されたラットの集団
GH:Globo H
SC:皮下
PBS:リン酸塩緩衝生理食塩水
実施例5.1 フローサイトメトリーによる免疫エフェクター細胞のサブポピュレーションの分析
実施例5.2 ELISAによるGlobo H−特異的抗体の試験
移動相B:95% CAN/0.1% FA
Claims (35)
- 次の構造を有する化合物:
nは独立的に1から1500の整数であり、
前記化合物のKLHは単量体、二量体、三量体、四量体、五量体、六量体、七量体、八量体、九量体、十量体、又はこれらの組み合わせであり、かつ
ここで各Globo H成分はKLH成分に対して、構造に示す通りリンカーを介して塩基性のアミノ酸残基上で共有結合性の結合をしており、かつ
ここで前記化合物の抗原決定基の割合は750から3000である。 - 前記化合物の前記KLHは単量体であり、nは1から150である、
請求項1の化合物。 - 前記化合物の前記KLHは二量体であり、nは1から300である、
請求項1の化合物。 - 前記化合物の前記KLHは三量体であり、nは1から450である、
請求項1の化合物。 - 前記化合物の前記KLHは四量体であり、nは1から600である、
請求項1の化合物。 - 前記化合物の前記KLHは五量体であり、nは1から750である、
請求項1の化合物。 - 次の構造を有する化合物と:
またここで前記化合物のKLHは単量体、二量体、三量体、四量体、五量体、六量体、七量体、八量体、九量体、十量体、又はこれらの組み合わせであり、
選択的に、薬剤として許容可能なキャリアと:
を有する医薬組成物であり、さらにここで
前記化合物の抗原決定基の割合は750から3000である。 - 前記化合物のKLHは単量体であり、nは1から150である、
請求項7の医薬組成物。 - 前記化合物のKLHは二量体であり、nは1から300である、
請求項7の医薬組成物。 - 前記化合物のKLHは三量体であり、nは1から450である、
請求項7の医薬組成物。 - 前記化合物のKLHは四量体であり、nは1から600である、
請求項7の医薬組成物。 - 前記化合物のKLHは五量体であり、nは1から750である、
請求項7の医薬組成物。 - 前記組成物中の前記化合物の1%から99%が単量体である、
請求項7の医薬組成物。 - 前記組成物中の前記化合物の1%から99%が二量体である、
請求項7の医薬組成物。 - 前記組成物中の前記化合物の1%から99%が三量体である、
請求項7の医薬組成物。 - 前記組成物中の前記化合物の1%から99%が四量体である、
請求項7の医薬組成物。 - 前記組成物中の前記化合物の1%から99%が五量体である、
請求項7の医薬組成物。 - さらにアジュバントを含有し、ここで
前記アジュバントは完全なフロインドアジュバント及び不完全なフロインドアジュバント、トール(Toll)様受容体分子、LPS、リポタンパク質、リポペプチド、フラジェリン、二重鎖RNA、ウイルスRNA、非メチル化CpGアイランド、レバミソール、カルメット・ゲラン桿菌、イソプリノシン、ザダキシン(Zadaxin)、PD-1拮抗物質、PD-1抗体、CTLA拮抗物質、CTLA抗体、インターロイキン、サイトカイン、GM-CSF、糖脂質、アルミニウム塩系物質、リン酸アルミニウム、ミョウバン、水酸化アルミニウム、リポソーム、TLR2作用物質、リポペプチド、ナノ粒子、モノホスホリルリピドA、OBI-821サポニン、水中油型ナノ乳剤、並びにバクテリア様粒子である、
請求項7の医薬組成物。 - IL-2、IL-12、IL-18、IL-2、IFN-γ、TNF、IL-4、IL-10、IL-13、IL-21、GM-CSF及びTGF-βからなる群から選ばれるサイトカインをさらに含有する、
請求項7の医薬組成物。 - さらにケモカインを含有する、
請求項7の医薬組成物。 - ホルモン療法剤(選択性エストロゲン受容体調節剤、アンドロゲン受容体調節剤等)、モノクローナル抗体療法、化学療法、レチノイド受容体調節剤、細胞傷害性薬物/細胞増殖抑制剤、抗腫瘍剤、抗増殖剤、プレニル−タンパク質転移酵素阻害剤、HMG-CoA還元酵素阻害剤、ナイトロジェンマスタード、ニトロソウレア、血管新生阻害剤(ベバシズマブ等)、細胞増殖及び生存シグナル経路の阻害剤、アポトーシス誘発剤、細胞周期チェックポイントを妨害する薬剤、受容体チロシンキナーゼ(RTKs)を妨害する薬剤、哺乳動物におけるラパマイシンの標的(mTOR)の阻害剤、ヒト上皮成長因子受容体2(HER2)阻害剤、上皮成長因子受容体(EGFR)阻害剤、インテグリン遮断薬、NSAID類、PPARアゴニスト、固有の多剤耐性(MDR)の阻害剤、抗嘔吐剤、貧血の治療において有用な薬剤、好中球減少症の治療において有用な薬剤、免疫増強薬、ビスホスホネート、アロマターゼ阻害剤、新生細胞の最終分化を誘導する薬剤、γセクレターゼ阻害剤、がんワクチン、PD-1/PD-L1阻害剤(細胞傷害性T細胞リンパ球(CTLs)免疫療法)、CTLA-4免疫療法、CDK4/6阻害剤(標的療法)、PI3K阻害剤(標的療法)、mTOR阻害剤(標的療法)、AKT阻害剤(標的療法)、Pan-Her阻害剤(標的療法)、並びにそれらの組み合わせ、からなる群から選ばれる薬剤をさらに含有する、
請求項7の医薬組成物。 - 医薬として許容可能なキャリアを含有する、
請求項7の医薬組成物。 - 前記医薬組成物はがんワクチンである、
請求項7の医薬組成物。 - 皮下注射用に処方される、
請求項7の医薬組成物。 - 静脈内投与用に処方される、
請求項7の医薬組成物。 - 筋肉内投与用に処方される、
請求項7の医薬組成物。 - がん治療を必要としているがん患者を治療するための、請求項7に記載の医薬組成物であって、
患者に投与し治療効果のある分量を投与する、医薬組成物。 - 前記がんは卵巣がんである、
請求項27の医薬組成物。 - 前記がんは上皮がんであり、
前記上皮がんは、乳がん、肺がん、肝がん、口腔がん、胃がん、結腸がん、鼻咽頭がん、皮膚がん、腎臓がん、脳腫瘍、前立腺がん、卵巣がん、子宮頸がん、子宮体がん、腸がん、膵臓がん、又は膀胱がんである、
請求項27の医薬組成物。 - 前記がんは乳がんである、
請求項27の医薬組成物。 - 前記組成物中の治療効果のある量のGlobo H成分が0.01μg/kgから250mg/kgである、
請求項27の医薬組成物。 - 前記組成物中の治療効果のある量のGlobo H成分が0.10μg/kgから0.75g/kgである、
請求項27の医薬組成物。 - 前記組成物中の治療効果のある量のGlobo-H-KLH複合体が0.01μg/kgから250mg/kgである、
請求項27の医薬組成物。 - 前記組成物中の治療効果のある量のGlobo-H-KLH複合体が0.60μg/kgから4.50μg/kgである、
請求項27の医薬組成物。 - 請求項1から6の前記化合物、及び請求項7から34の前記医薬組成物のいずれかの、動物又はヒトにおいて抗体を誘導するための製剤の製造における使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361878982P | 2013-09-17 | 2013-09-17 | |
US61/878,982 | 2013-09-17 | ||
PCT/IB2014/002744 WO2015159118A2 (en) | 2013-09-17 | 2014-09-15 | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016540099A JP2016540099A (ja) | 2016-12-22 |
JP6431920B2 true JP6431920B2 (ja) | 2018-11-28 |
Family
ID=53935288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016543472A Active JP6431920B2 (ja) | 2013-09-17 | 2014-09-15 | 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 |
Country Status (19)
Country | Link |
---|---|
US (1) | US12053514B2 (ja) |
EP (1) | EP3046588B1 (ja) |
JP (1) | JP6431920B2 (ja) |
KR (1) | KR20160055861A (ja) |
CN (1) | CN105764921B (ja) |
AR (1) | AR097661A1 (ja) |
AU (2) | AU2014391422A1 (ja) |
BR (1) | BR112015032713B1 (ja) |
CA (1) | CA2924286C (ja) |
CL (1) | CL2016000538A1 (ja) |
ES (1) | ES2914176T3 (ja) |
HK (2) | HK1221476A1 (ja) |
IL (1) | IL242907B (ja) |
NZ (1) | NZ714555A (ja) |
PH (1) | PH12015502629A1 (ja) |
RU (1) | RU2666141C2 (ja) |
SG (1) | SG11201510740YA (ja) |
TW (1) | TWI641383B (ja) |
WO (1) | WO2015159118A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ714555A (en) | 2013-09-17 | 2020-03-27 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
CN106456766B (zh) | 2014-03-19 | 2020-03-10 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 抗免疫原性糖肽的抗体、包含其的组合物及其用途 |
KR102679516B1 (ko) * | 2014-09-15 | 2024-07-02 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료적 당접합체 조성물 및 그의 용도 |
CN108350605A (zh) | 2015-09-04 | 2018-07-31 | 台湾浩鼎生技股份有限公司 | 聚糖阵列以及使用方法 |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
CA3019560A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
US11583577B2 (en) | 2016-04-22 | 2023-02-21 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
US11642400B2 (en) * | 2016-07-27 | 2023-05-09 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
TW201825522A (zh) * | 2016-09-23 | 2018-07-16 | 張志隆 | 抗-globo h 抗體 |
TWI767959B (zh) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
JP2021525756A (ja) * | 2018-06-01 | 2021-09-27 | オービーアイ ファーマ,インコーポレイテッド | 抗グロボh又は抗ssea−4抗体を、抗ネガティブ免疫チェックポイント抗体と共に使用することによる組合せ療法 |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
CN112924700A (zh) * | 2021-01-26 | 2021-06-08 | 海南医学院 | 一种钥孔血蓝蛋白(KLH)的包被工艺及小鼠KLH特异性IgG抗体定量检测试剂盒 |
MX2023013845A (es) * | 2021-05-24 | 2023-12-08 | Cha Vaccine Res Institute Co Ltd | Composicion terapeutica para inmunooncologia usando un adyuvante que incluye lipopeptidos y acido poliinosinico:policitidilico (poli (i:c)). |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
AU519567B2 (en) * | 1977-07-13 | 1981-12-10 | Akzo Nv | Psychopharmacological penta and hexa-peptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4849222A (en) | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586515B1 (en) | 1991-04-30 | 1997-09-17 | Eukarion, Inc. | Cationized antibodies against intracellular proteins |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2137558A1 (en) | 1992-07-17 | 1994-02-03 | Wayne A. Marasco | Method of intracellular binding of target molecules |
CA2141216A1 (en) | 1992-07-27 | 1994-02-03 | Michael J. Micklus | Targeting of liposomes to the blood-brain barrier |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
DK0724432T3 (da) | 1993-10-22 | 2003-01-27 | Genentech Inc | Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner |
US6544952B1 (en) * | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
EP1110953B1 (en) | 1995-03-30 | 2009-10-28 | Pfizer Products Inc. | Quinazoline derivatives |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
CA2365250A1 (en) | 1999-02-17 | 2000-08-24 | Glycominds Ltd. | Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof |
US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
US7824687B2 (en) * | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
AU2002338446A1 (en) | 2001-01-23 | 2002-11-05 | University Of Rochester Medical Center | Methods of producing or identifying intrabodies in eukaryotic cells |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
EP1458242A4 (en) * | 2001-07-06 | 2006-06-07 | Sloan Kettering Inst Cancer | COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER |
DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
EP1429785A4 (en) * | 2001-08-14 | 2005-12-14 | Biomira Inc | IMMUNOGENIC CONJUGATE OF GLUCIDIC HAPTENES AND AGREED PROTEIN MEDIUM |
AU2002363939A1 (en) | 2001-11-20 | 2003-06-10 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
WO2003077945A1 (en) | 2002-03-14 | 2003-09-25 | Medical Research Council | Intracellular antibodies |
WO2004032828A2 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US20060035267A1 (en) | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
US7579452B2 (en) * | 2003-08-25 | 2009-08-25 | Oncomune, Llc | Cancer vaccine based on brother of regulator of imprinted sites molecule |
EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
EP1723422A2 (en) | 2004-03-05 | 2006-11-22 | The Scripps Research Institute | High throughput glycan microarrays |
JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ, リミテッド | 先天免疫応答を誘導するための方法および組成物 |
NZ553244A (en) | 2004-07-18 | 2009-10-30 | Csl Ltd | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
CN103356703B (zh) | 2005-03-31 | 2016-04-06 | 斯丹姆涅恩有限公司 | 制备用以治疗慢性感染伤口的药物的方法 |
BRPI0617165B1 (pt) | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
CA2626238C (en) | 2005-10-17 | 2015-10-06 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
EP1984401A2 (en) * | 2006-01-31 | 2008-10-29 | Novartis AG | Il-17 antagonistic antibodies fpr treating cancer |
JP5391073B2 (ja) | 2006-11-27 | 2014-01-15 | ディアデクサス インコーポレーテッド | Ovr110抗体組成物および使用方法 |
WO2009035494A2 (en) | 2007-07-30 | 2009-03-19 | The Scripps Research Institute | Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease |
CA2701612A1 (en) * | 2007-10-05 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Neuromedin u derivative |
EP2268315B1 (en) * | 2008-03-31 | 2019-07-31 | Freie Universität Berlin | Drug conjugates with polyglycerols |
CA2720771C (en) | 2008-04-08 | 2018-03-20 | Sloan-Kettering Institute For Cancer Research | Triterpene saponins, methods of synthesis, and uses thereof |
KR20110031949A (ko) | 2008-06-16 | 2011-03-29 | 아카데미아 시니카 | Globo h 및 ssea3에 특이적인 면역 반응을 유도하기 위한 조성물 및 암 치료에서의 이의 용도 |
CN105535955B (zh) | 2009-06-16 | 2019-04-23 | 中央研究院 | Globo h及含新颖糖脂质佐剂的相关抗癌疫苗 |
EP2347769A1 (en) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
CA2801922A1 (en) * | 2010-06-11 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Multivalent glycopeptide constructs and uses thereof |
EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
JP5926374B2 (ja) * | 2011-06-10 | 2016-05-25 | メルサナ セラピューティクス,インコーポレイティド | タンパク質−高分子−薬剤コンジュゲート |
WO2013126746A2 (en) | 2012-02-24 | 2013-08-29 | Stem Centrx, Inc. | Novel modulators and methods of use |
DK2825156T3 (en) | 2012-03-16 | 2017-10-30 | Merck Patent Gmbh | TARGETED AMINO ACID LIPIDS |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
AU2014203977B2 (en) | 2013-01-04 | 2016-11-17 | Obi Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
WO2014178195A1 (ja) | 2013-05-02 | 2014-11-06 | 独立行政法人産業技術総合研究所 | 糖鎖抗原の免疫誘導剤 |
NZ714555A (en) | 2013-09-17 | 2020-03-27 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
JP2017507118A (ja) | 2014-01-16 | 2017-03-16 | アカデミア シニカAcademia Sinica | がんの処置および検出のための組成物および方法 |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CN106456766B (zh) | 2014-03-19 | 2020-03-10 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 抗免疫原性糖肽的抗体、包含其的组合物及其用途 |
EP2927328B1 (en) | 2014-04-01 | 2018-10-10 | Miltenyi Biotec GmbH | SSEA4 and ST3GAL2 as chemotherapeutic drug response biomarkers |
RU2016138744A (ru) | 2014-04-10 | 2018-05-11 | Оби Фарма Инк. | Антитела, фармацевтические композиции и их применения |
CA2958757C (en) | 2014-08-19 | 2021-04-27 | Miltenyi Biotec Gmbh | Chimeric antigen receptor specific for ssea4 antigen |
KR102679516B1 (ko) | 2014-09-15 | 2024-07-02 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료적 당접합체 조성물 및 그의 용도 |
EP3248013B1 (en) | 2015-01-24 | 2020-07-15 | Academia Sinica | Cancer markers and methods of use thereof |
AU2016285859A1 (en) | 2015-06-29 | 2018-02-15 | The Johns Hopkins University | Immune checkpoint chimeric antigen receptors therapy |
CN108350605A (zh) | 2015-09-04 | 2018-07-31 | 台湾浩鼎生技股份有限公司 | 聚糖阵列以及使用方法 |
CA3000531A1 (en) | 2015-10-07 | 2017-04-13 | Obi Pharma, Inc. | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
CA3019560A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
US11583577B2 (en) | 2016-04-22 | 2023-02-21 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
US11642400B2 (en) | 2016-07-27 | 2023-05-09 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
US20180030124A1 (en) | 2016-07-29 | 2018-02-01 | Lan Bo Chen | Methods and compositions for enhancing anti-ssea4 immunotherapy |
KR102588027B1 (ko) | 2016-08-22 | 2023-10-12 | 초 파마 인크. | 항체, 결합 단편 및 사용 방법 |
TWI767959B (zh) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
JP2021525756A (ja) | 2018-06-01 | 2021-09-27 | オービーアイ ファーマ,インコーポレイテッド | 抗グロボh又は抗ssea−4抗体を、抗ネガティブ免疫チェックポイント抗体と共に使用することによる組合せ療法 |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
-
2014
- 2014-09-15 NZ NZ714555A patent/NZ714555A/en unknown
- 2014-09-15 SG SG11201510740YA patent/SG11201510740YA/en unknown
- 2014-09-15 AU AU2014391422A patent/AU2014391422A1/en not_active Abandoned
- 2014-09-15 CA CA2924286A patent/CA2924286C/en active Active
- 2014-09-15 ES ES14889702T patent/ES2914176T3/es active Active
- 2014-09-15 EP EP14889702.8A patent/EP3046588B1/en active Active
- 2014-09-15 AR ARP140103428A patent/AR097661A1/es unknown
- 2014-09-15 BR BR112015032713-3A patent/BR112015032713B1/pt active IP Right Grant
- 2014-09-15 KR KR1020167009483A patent/KR20160055861A/ko active Search and Examination
- 2014-09-15 JP JP2016543472A patent/JP6431920B2/ja active Active
- 2014-09-15 CN CN201480044491.8A patent/CN105764921B/zh active Active
- 2014-09-15 WO PCT/IB2014/002744 patent/WO2015159118A2/en active Application Filing
- 2014-09-15 RU RU2015150769A patent/RU2666141C2/ru active
- 2014-09-16 TW TW103131876A patent/TWI641383B/zh active
- 2014-09-17 US US14/489,182 patent/US12053514B2/en active Active
-
2015
- 2015-11-25 PH PH12015502629A patent/PH12015502629A1/en unknown
- 2015-12-03 IL IL242907A patent/IL242907B/en active IP Right Grant
-
2016
- 2016-03-09 CL CL2016000538A patent/CL2016000538A1/es unknown
- 2016-08-10 HK HK16109563.0A patent/HK1221476A1/zh unknown
- 2016-09-13 HK HK16110810.9A patent/HK1222569A1/zh unknown
-
2019
- 2019-01-17 AU AU2019200314A patent/AU2019200314B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2666141C2 (ru) | 2018-09-06 |
EP3046588A4 (en) | 2017-05-31 |
KR20160055861A (ko) | 2016-05-18 |
HK1221476A1 (zh) | 2017-06-02 |
BR112015032713B1 (pt) | 2023-03-21 |
CN105764921A (zh) | 2016-07-13 |
ES2914176T3 (es) | 2022-06-07 |
BR112015032713A2 (pt) | 2018-03-20 |
CL2016000538A1 (es) | 2016-10-28 |
TW201521766A (zh) | 2015-06-16 |
US12053514B2 (en) | 2024-08-06 |
TWI641383B (zh) | 2018-11-21 |
EP3046588B1 (en) | 2022-03-02 |
CN105764921B (zh) | 2020-06-30 |
IL242907B (en) | 2020-11-30 |
AU2019200314B2 (en) | 2020-07-02 |
CA2924286C (en) | 2022-06-21 |
AU2014391422A1 (en) | 2015-12-17 |
RU2015150769A (ru) | 2017-10-23 |
JP2016540099A (ja) | 2016-12-22 |
HK1222569A1 (zh) | 2017-07-07 |
PH12015502629B1 (en) | 2016-03-07 |
WO2015159118A3 (en) | 2016-03-17 |
PH12015502629A1 (en) | 2016-03-07 |
WO2015159118A2 (en) | 2015-10-22 |
US20150297696A1 (en) | 2015-10-22 |
SG11201510740YA (en) | 2016-01-28 |
EP3046588A2 (en) | 2016-07-27 |
AR097661A1 (es) | 2016-04-06 |
NZ714555A (en) | 2020-03-27 |
AU2019200314A1 (en) | 2019-02-07 |
CA2924286A1 (en) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6431920B2 (ja) | 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 | |
TWI752988B (zh) | 免疫性/治療性聚醣組合物及其用途 | |
KR102702705B1 (ko) | 면역원성/치료적 당접합체 조성물 및 그의 용도 | |
TWI392502B (zh) | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171113 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180530 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181016 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6431920 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |